

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

**VOLUNTARY ANNOUNCEMENT  
ASPIRATION CATHETER AND SUPPORT CATHETER  
RECEIVED NMPA APPROVALS**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The Company is pleased to announce that the Company has recently received the approvals from the National Medical Products Administration of the PRC (國家藥品監督管理局) (“**NMPA**”) for the registration applications for the Aspiration Catheter and Support Catheter.

The Aspiration Catheter is used in the aspiration thrombectomy procedure to retrieve the thrombus and restore blood flow in occluded cerebral vessels for AIS-LVO patients. The Support Catheter is one of the vascular access devices used in neuro-interventional procedures.

As of the date of this announcement, the Company has obtained 13 NMPA approved products in total in the four aspects of the neuro-interventional treatment device market, and the newly approved products make the Company the first player to offer a full domestic product portfolio covering both stent retrieving and aspiration thrombectomy in China.

There is no assurance that the Aspiration Catheter and Support Catheter will ultimately be successfully marketed and/or commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, April 26, 2022

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*